<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838574</url>
  </required_header>
  <id_info>
    <org_study_id>2021/CHU/03</org_study_id>
    <nct_id>NCT04838574</nct_id>
  </id_info>
  <brief_title>Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years</brief_title>
  <acronym>ChikRhuma15</acronym>
  <official_title>Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reunion Island was struck by a severe Chikungunya outbreak in 2005-2006. Three hundred and&#xD;
      seven Chikungunya patients were evaluated by 4 rheumatologists 2 months after the initial&#xD;
      infection (RHUMATOCHIK study). Eighty-three percents still reported joint pain and 43% joint&#xD;
      swelling in telephone interviews after 32 months (Bouquillard et al., 2018). The primary&#xD;
      objective of the present study is to assess and classify precisely persistent Chi-related&#xD;
      joint diseases after 15 years, in a second rheumatology examination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reunion Island was struck in 2005-2006 by the most severe Chikungunya outbreak&#xD;
      (seroprevalence 38% (Gérardin et al., 2013)) in a developed but previously non-immunized&#xD;
      country, providing an unique opportunity for studying Chikungunya-related joint symptoms and&#xD;
      their long-term evolution. In a previous study, the investigators demonstrated that at least&#xD;
      17/73 patients initially classified as Chikungunya-related inflammatory joint diseases after&#xD;
      40 months still suffered from inflammatory joint symptoms fullfilling validated&#xD;
      classification criteria after 13 years (Guillot et al., 2020). However, in this monocentric&#xD;
      study, the investigators did not consider the full spectrum of Chikungunya-related rheumatic&#xD;
      diseases, the population was not fully representative and the sample size was not sufficient&#xD;
      to perform statistical analyses nor identify poor prognosis markers. In the RHUMATOCHIK&#xD;
      cohort study, 307 patients were evaluated by 4 rheumatologists 2 months after the infection,&#xD;
      83% and 43% reported persistent joint pain and joint swelling respectively after 32 months in&#xD;
      potentially biased telephone interviews (Bouquillard et al., 2018).&#xD;
&#xD;
      In this context, the present study aims at performing a systematic clinical rheumatologic&#xD;
      re-evaluation of the RHUMATOCHIK patients after 15 years, in order to precisely describe and&#xD;
      classify the full spectrum of persistent Chikungunya-related joint diseases in a larger&#xD;
      population.&#xD;
&#xD;
      After a telephone interview and screening questionnaire, these patients will be clinically&#xD;
      re-evaluated by a second rheumatologist in a multicenter transversal follow-up study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the phenotype of chronic post-Chikungunya rheumatological pictures persisting 15 years after the initial infection</measure>
    <time_frame>Day 0</time_frame>
    <description>The primary outcome is the distribution (%) of rheumatic disease types among the patients with persistent Chikungunya-related rheumatic symptoms after 15 years ie. the percentage of patients fullfilling validated classification criteria of inflammatory rheumatic diseases (Rheumatoid Arthritis (Aletaha et al., 2010), Spondyloarthritis (Dougados et al., 1991; Rudwaleit et al., 2011a), Psoriatic Arthritis (Taylor et al., 2006), RS3PE - or undifferentiated arthritis), or classified in other rheumatic diseases (osteoarthritis, tendinitis, capsulitis, carpal tunnel syndrome, radicular pain, crystal-induced arthritis (Neogi et al., 2015), fibromyalgia (Wolfe et al., 2011)) - at inclusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the phenotype of post-Chikungunya chronic rheumatological pictures that have resolved 15 years after the initial infection.</measure>
    <time_frame>Day 0</time_frame>
    <description>The distribution (%) of rheumatic disease types among the patients with no more Chikungunya-related rheumatic symptoms after 15 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To specify the time of onset in relation to the initial infection of rheumatological pictures initially attributed to Chikungunya.</measure>
    <time_frame>Day 0</time_frame>
    <description>The mean duration (months) of Chikungunya-related rheumatic diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing of onset of rheumatologic symptomatology in relation to CHIKV infection</measure>
    <time_frame>Day 0</time_frame>
    <description>Date of infection, date of onset of rheumatologic symptoms, time between the two (months), average duration (months) of rheumatologic symptomatology attributed to CHIKV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatological pictures pre-existing the infection</measure>
    <time_frame>Day 0</time_frame>
    <description>Comparison of patients with persistent versus resolving Chikungunya-related rheumatic diseases after 15 years, in order to identify prognostic factors</description>
  </secondary_outcome>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Chikungunya</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>15 years Follow-up group</intervention_name>
    <description>Phone recruitment, screening interview and eligibility questionnaire. Patient inclusion during rheumatologic evaluation : questionnaire, examination and data collection in one of the 4 study hospital centers.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients previously included in the RHUMATOCHIK study, or diagnosed as&#xD;
        Chikungunya-related Rheumatoid Arthritis in the Reunion Island.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients previously included in the RHUMATOCHIK study (N=307), or diagnosed as&#xD;
             Chikungunya-related Rheumatoid Arthritis (N=21) after telephonic screening and given&#xD;
             their oral consent&#xD;
&#xD;
          -  Chikungunya infection (positive serology and/or evocative symptoms in the epidemic&#xD;
             context)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossible informed consent (cognitive impairment,…).&#xD;
&#xD;
          -  Lost-to-follow-up patients, refusal to participate. -Pre-existing chronic inflammatory&#xD;
             rheumatic disease (prior to CHIKV infection)-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xavier GUILLOT</last_name>
    <phone>0262 90 59 20</phone>
    <email>xavier.guillot@chu-reunion.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>GH Est Réunion</name>
      <address>
        <city>Saint-Benoît</city>
        <country>Réunion</country>
      </address>
    </facility>
    <contact>
      <last_name>Elsa DENOIX</last_name>
      <email>elsa.denoix@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Elsa DENOIX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier GUILLOT</last_name>
      <email>xavier.guillot@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier GUILLOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith PAYET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Ouest Réunion</name>
      <address>
        <city>Saint-Paul</city>
        <country>Réunion</country>
      </address>
    </facility>
    <contact>
      <last_name>Julia GOOSSENS</last_name>
      <email>Ju.GOOSSENS@chor.re</email>
    </contact>
    <investigator>
      <last_name>Julia GOOSSENS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Réunion</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chikungunya Fever</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

